|  |  |  |
| --- | --- | --- |
| **Patients without cirrhosis, AS-AIH and treated with azathioprine** | | |
|  | **STD (%) pre-IPTW** | **STD (%) post-IPTW** |
| Female sex | 4.5 | 10.1 |
| Age, years | 6.2 | 16.1 |
| AST, IU/L | 81.3 | 20.9 |
| ALT, IU/L | 72.3 | 17.4 |
| ALP, IU/L | 28.3 | 0.4 |
| GGT, IU/L | 14.1 | 7.1 |
| Bilirubin, mg/dL | 71 | 13.4 |
| INR | 34.3 | 9.2 |
| ANA ≥1/80 | 2.3 | 15.5 |
| ASMA ≥1/40 | 9.5 | 6.7 |
| IgG mg/dL | 12.1 | 9.5 |
| Ferritin >2.1-fold-ULN | 46.8 | 3.3 |
| **Entire cohort** | | |
|  | **STD (%) pre-IPTW** | **STD (%) post-IPTW** |
| Female sex | 1.0 | 11.2 |
| Age, years | 9.4 | 3.4 |
| Cirrhosis | 39.6 | 16.7 |
| AST, IU/L | 82.5 | 6.3 |
| ALT, IU/L | 64.1 | 7.5 |
| ALP, IU/L | 34.3 | 9.1 |
| GGT, IU/L | 24.2 | 0.6 |
| Bilirubin, mg/dL | 76.3 | 0.7 |
| INR | 4.7 | 10.5 |
| ANA ≥1/80 | 4.3 | 7.4 |
| ASMA ≥1/40 | 16.1 | 1.1 |
| IgG mg/dL | 22.0 | 9.7 |
| Azathioprine | 8.4 | 1.2 |
| Ferritin >2.1-fold-ULN | 49.6 | 4.9 |

**Supplementary table 3**. Standardized mean differences after the application of the inverse probability of treatment weighting (IPTW) propensity score.

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transpeptidase; INR: International normalized ratio; IgG: Immunoglobulin G;   
ANA: Anti-nuclear antibodies; ASMA: Anti-Smooth Muscle Antibodies